[1] |
Marx RE. Pamidronate(Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
doi: 10.1016/S0278-2391(03)00720-1
URL
|
[2] |
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
doi: 10.1016/j.joms.2014.04.031
URL
|
[3] |
Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37(25): 2270-2290.
doi: 10.1200/JCO.19.01186
pmid: 31329513
|
[4] |
Khan AA, Morrison A, Kendler DL, et al. Case-based review of osteonecrosis of the jaw(ONJ) and application of the international recommendations for management from the international task force on ONJ[J]. J Clin Densitom, 2017, 20(1): 8-24.
doi: 10.1016/j.jocd.2016.09.005
URL
|
[5] |
Moraschini V, Calasans-Maia MD, Louro RS, et al. Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses[J]. J Oral Pathol Med, 2021, 50(1): 10-21.
doi: 10.1111/jop.v50.1
URL
|
[6] |
Rugani P, Acham S, Kirnbauer B, et al. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series[J]. Clin Oral Investig, 2015, 19(6): 1329-1338.
doi: 10.1007/s00784-014-1384-1
URL
|
[7] |
Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw[J]. J Bone Miner Metab, 2017, 35(1): 6-19.
doi: 10.1007/s00774-016-0810-7
pmid: 28035494
|
[8] |
Lorenzo-Pouso AI, Pérez-Sayáns M, Chamorro-Petronacci C, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis[J]. J Oral Pathol Med, 2020, 49(3): 190-200.
doi: 10.1111/jop.12963
pmid: 31605632
|
[9] |
AlRahabi MK, Ghabbani HM. Clinical impact of bisphosphonates in root canal therapy[J]. Saudi Med J, 2018, 39(3): 232-238.
doi: 10.15537/smj.2018.3.20923
pmid: 29543299
|
[10] |
Kim KM, Rhee Y, Kwon YD, et al. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean society for bone and mineral research and the Korean association of oral and maxillofacial surgeons[J]. J Bone Metab, 2015, 22(4): 151-165.
doi: 10.11005/jbm.2015.22.4.151
URL
|
[11] |
郭玉兴, 王佃灿, 刘筱菁, 等. 翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J]. 中华口腔医学杂志, 2021, 56(5): 452-457.
|
[12] |
Fede OD, Panzarella V, Mauceri R, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention[J]. Biomed Res Int, 2018: 2684924.
|
[13] |
Hasegawa T, Kawakita A, Ueda N, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: Can primary wound closure and a drug holiday really prevent MRONJ?[J]. Osteoporos Int, 2017, 28(8): 2465-2473.
doi: 10.1007/s00198-017-4063-7
pmid: 28451732
|
[14] |
Niibe K, Ouchi T, Iwasaki R, et al. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab[J]. J Prosthodont Res, 2015, 59(1): 3-5.
doi: 10.1016/j.jpor.2014.08.001
pmid: 25212129
|
[15] |
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus[J]. J Bone Miner Res, 2015, 30(1): 3-23.
doi: 10.1002/jbmr.2405
pmid: 25414052
|
[16] |
Bermúdez-Bejarano EB, Serrera-Figallo Má, Gutiérrez-Corrales A, et al. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates[J]. J Clin Exp Dent, 2017, 9(1): e141-e149.
|
[17] |
Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 251-255.
doi: 10.1016/j.ijom.2009.11.014
URL
|
[18] |
Epstein MS, Wicknick FW, Epstein JB, et al. Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(5): 593-596.
doi: 10.1016/j.tripleo.2010.05.067
pmid: 20955948
|
[19] |
Akashi M, Kusumoto J, Takeda D, et al. A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw[J]. Oral Maxillofac Surg, 2018, 22(4): 369-378.
doi: 10.1007/s10006-018-0732-8
pmid: 30327979
|
[20] |
Weber JBB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw(BRONJ): A systematic review[J]. Lasers Med Sci, 2016, 31(6): 1261-1272.
doi: 10.1007/s10103-016-1929-4
URL
|
[21] |
Latifyan S, Genot MT, Klastersky J. Bisphosphonate-related osteonecrosis of the jaw: A review of the potential efficacy of low-level laser therapy[J]. Support Care Cancer, 2016, 24(9): 3687-3693.
doi: 10.1007/s00520-016-3139-9
pmid: 27029476
|
[22] |
Vescovi P, Manfredi M, Merigo E, et al. Surgical approach with Er: YAG laser on osteonecrosis of the jaws(ONJ) in patients under bisphosphonate therapy(BPT)[J]. Lasers Med Sci, 2010, 25(1): 101-113.
doi: 10.1007/s10103-009-0687-y
URL
|
[23] |
Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series[J]. J Oral Maxillofac Surg, 2007, 65(7): 1321-1327.
doi: 10.1016/j.joms.2007.03.019
URL
|
[24] |
Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics[J]. J Oral Maxillofac Surg, 2012, 70(7): 1573-1583.
doi: 10.1016/j.joms.2012.04.001
URL
|
[25] |
Sacco R, Leeson R, Nissan J, et al. A systematic review of oxygen therapy for the management of medication-related osteonecrosis of the jaw (MRONJ)[J]. Appl Sci, 2019, 9(5): 1026.
doi: 10.3390/app9051026
URL
|
[26] |
Agrillo A, Petrucci MT, Tedaldi M, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws[J]. J Craniofac Surg, 2006, 17(6): 1080-1083.
pmid: 17119409
|
[27] |
Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial[J]. J Clin Oncol, 2020, 38(26): 2971-2980.
doi: 10.1200/JCO.19.02192
URL
|
[28] |
dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis[J]. Osteoporos Int, 2021, 32(12): 2449-2459.
doi: 10.1007/s00198-021-06078-z
|
[29] |
Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis[J]. J Oral Maxillofac Surg, 2014, 72(2): 334-337.
doi: 10.1016/j.joms.2013.06.188
URL
|
[30] |
Ziebart T, Koch F, Klein MO, et al. Geranylgeraniol — a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw[J]. Oral Oncol, 2011, 47(3): 195-201.
doi: 10.1016/j.oraloncology.2010.12.003
pmid: 21247791
|
[31] |
Giudice A, Barone S, Diodati F, et al. Can surgical management improve resolution of medication-related osteonecrosis of the jaw at early stages? A prospective cohort study[J]. J Oral Maxillofac Surg, 2020, 78(11): 1986-1999.
doi: 10.1016/j.joms.2020.05.037
URL
|
[32] |
Ristow O, Otto S, Troeltzsch M, et al. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)[J]. J Craniomaxillofac Surg, 2015, 43(2): 290-293.
doi: 10.1016/j.jcms.2014.11.014
pmid: 25541255
|
[33] |
Ristow O, Rückschloß T, Müller M, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study[J]. J Craniomaxillofac Surg, 2019, 47(3): 491-499.
doi: S1010-5182(18)30593-6
pmid: 30642734
|
[34] |
Hayashida S, Soutome S, Yanamoto S, et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32(10): 2022-2029.
doi: 10.1002/jbmr.3191
pmid: 28585700
|
[35] |
Tomo S, da Cruz TM, Figueira JA, et al. Fluorescence-guided surgical management of medication-related osteonecrosis of the jaws[J]. Photodiagnosis Photodyn Ther, 2020, 32: 102003.
doi: 10.1016/j.pdpdt.2020.102003
URL
|
[36] |
Ristow O, Otto S, Geiß C, et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: A randomized controlled feasibility study[J]. Int J Oral Maxillofac Surg, 2017, 46(2): 157-166.
|
[37] |
Blus C, Giannelli G, Szmukler-Moncler S, et al. Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites[J]. Oral Maxillofac Surg, 2017, 21(1): 41-48.
doi: 10.1007/s10006-016-0597-7
pmid: 27924427
|
[38] |
Pellegrino G, Pavanelli F, Ferri A, et al. Ultrasonic navigation for the treatment of medication-related jaw osteonecrosis involving the inferior alveolar nerve: A case report and protocol review[J]. Methods Protoc, 2020, 3(4): 70.
doi: 10.3390/mps3040070
URL
|
[39] |
Aljohani S, Troeltzsch M, Hafner S, et al. Surgical treatment of medication-related osteonecrosis of the upper jaw: Case series[J]. Oral Dis, 2019, 25(2): 497-507.
doi: 10.1111/odi.12992
pmid: 30325561
|
[40] |
Melville JC, Tursun R, Shum JW, et al. A technique for the treatment of oral-antral fistulas resulting from medication-related osteonecrosis of the maxilla: The combined buccal fat pad flap and radical sinusotomy[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(3): 287-291.
doi: 10.1016/j.oooo.2016.03.015
URL
|
[41] |
Ristow O, Rückschloß T, Bodem J, et al. Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw — A single center cohort study[J]. J Craniomaxillofac Surg, 2018, 46(5): 815-824.
doi: 10.1016/j.jcms.2018.03.005
URL
|
[42] |
Eckardt AM, Kokemüller H, Tavassol F, et al. Reconstruction of oral mucosal defects using the nasolabial flap: clinical experience with 22 patients[J]. Head Neck Oncol, 2011, 3: 28.
doi: 10.1186/1758-3284-3-28
pmid: 21605443
|
[43] |
Lemound J, Muecke T, Zeller AN, et al. Nasolabial flap improves healing in medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2018, 76(4): 877-885.
doi: 10.1016/j.joms.2017.09.021
URL
|
[44] |
Ye P, Wei T, Lu ZY, et al. The role of autologous platelet concentrates in the treatment of medication-related osteonecrosis of the jaw[J]. J Craniofac Surg, 2021, 32(2): 621-625.
doi: 10.1097/SCS.0000000000006976
URL
|
[45] |
Cortese A, Casarella A, Howard CM, et al. Epi-mucosa fixation and autologous platelet-rich fibrin treatment in medication-related osteonecrosis of the jaw[J]. Dent J (Basel), 2021, 9(5): 50.
|
[46] |
Yüce MO, Adalı E, Işık G. The effect of concentrated growth factor(CGF) in the surgical treatment of medication-related osteonecrosis of the jaw(MRONJ) in osteoporosis patients: A randomized controlled study[J]. Clin Oral Investig, 2021, 25(7): 4529-4541.
doi: 10.1007/s00784-020-03766-8
|
[47] |
Cicciù M, Herford AS, Juod/u017ebalys G, et al. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw[J]. J Craniofac Surg, 2012, 23(3): 784-788.
doi: 10.1097/SCS.0b013e31824dbdd4
pmid: 22565901
|
[48] |
Carreira AC, Lojudice FH, Halcsik E, et al. Bone morphogenetic proteins: Facts, challenges, and future perspectives[J]. J Dent Res, 2014, 93(4): 335-345.
doi: 10.1177/0022034513518561
pmid: 24389809
|
[49] |
Vanpoecke J, Verstraete L, Smeets M, et al. Medication-related osteonecrosis of the jaw (MRONJ) stage Ⅲ: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review[J]. J Craniomaxillofac Surg, 2020, 48(4): 435-443.
doi: S1010-5182(20)30055-X
pmid: 32178949
|
[50] |
Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection[J]. J Oral Maxillofac Surg, 2014, 72(4): 655-657.
doi: 10.1016/j.joms.2013.12.007
URL
|
[51] |
田美, 孙国文, 王丹妮, 等. 不同手术方法治疗双膦酸盐性颌骨坏死[J]. 中华整形外科杂志, 2020, 36(5): 540-545.
|
[52] |
Sacco R, Umar G, Guerra RC, et al. Evaluation of segmental mandibular resection without microvascular reconstruction in patients affected by medication-related osteonecrosis of the jaw: A systematic review[J]. Br J Oral Maxillofac Surg, 2021, 59(6): 648-660.
doi: 10.1016/j.bjoms.2020.12.014
URL
|
[53] |
Caldroney S, Ghazali N, Dyalram D, et al. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw[J]. Int J Oral Maxillofac Surg, 2017, 46(7): 871-876.
doi: 10.1016/j.ijom.2017.01.023
URL
|
[54] |
Vercruysse H Jr, de Backer T, Mommaerts MY. Outcomes of osseous free flap reconstruction in stage Ⅲ bisphosphonate-related osteonecrosis of the jaw: Systematic review and a new case series[J]. J Cranio Maxillofac Surg, 2014, 42(5): 377-386.
doi: 10.1016/j.jcms.2014.01.005
URL
|
[55] |
Mücke T, Jung M, Koerdt S, et al. Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy[J]. J Craniomaxillofac Surg, 2016, 44(2): 142-147.
doi: 10.1016/j.jcms.2015.11.015
pmid: 26752221
|
[56] |
田美, 王丹妮, 罗舒艳, 等. 上颌骨药物相关性颌骨坏死的手术治疗效果初探[J]. 中华口腔医学杂志, 2021, 56(5): 447-451.
|